ULTIMOVACS

Ultimovacs is a clinical-stage biotechnology company developing novel immunotherapies against cancer. The product candidate UV1 is an off-the-shelf therapeutic cancer vaccine designed to enhance the benefits of immunotherapy and improve cancer treatment efficacy for patients. UV1 triggers an immune response against the shared cancer antigen telomerase, a target present in 85-90% of all cancer indications across disease stages... Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. We enable the immune system to fight cancer... Ultimovacs is developing a new type of cancer treatment. We are currently evaluating the safety and efficacy. We have not secured regulatory approval and so we are not able to use the treatment outside of our clinical trial program.

Also known as: Ultimovacs ASA

Primary location: Oslo